Clareo Health | LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
3. Stable body weight defined as less than 5% self-reported change in body weight 3 months prior to the screening or during the period between the historical biopsy and randomisation, if a historical biopsy is used
You may not be if
1. Any of the following liver laboratory test abnormalities at screening:
* Serum AST and/or alanine aminotransferase (ALT) elevation ≥5x upper limit of normal (ULN)
* Platelet count \<140 000/mm\^3 (\<140 GI/L)
* Alkaline phosphatase \>2x upper limit of normal (ULN)
* Abnormal synthetic liver function as defined by screening central laboratory evaluation:
* Albumin below \<3.5 g/dL (35.0 g/L)
* OR International normalised ratio (INR) of prothrombin time \>1.3
* OR total serum bilirubin concentration ≥1.5x ULN
2. Any history or evidence of acute or chronic liver disease other than MASH
3. Histologically documented liver cirrhosis (fibrosis stage F4), either at screening or in a historical biopsy
4. History of or current diagnosis of hepatocellular carcinoma
5. History of or planned liver transplant
6. Inability or unwillingness to undergo a liver biopsy at screening (if a suitable historical biopsy is unavailable for central review), or during trial conduct.
7. History of portal hypertension or presence of decompensated liver disease
